
Quarterly report 2025-Q3
added 10-31-2025
Laboratory Corporation of America Holdings Cash Flow 2011-2026 | LH
Annual Cash Flow Laboratory Corporation of America Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
1.59 B | 1.33 B | 1.96 B | 3.11 B | 2.14 B | 1.44 B | 1.31 B | 1.5 B | 1.2 B | 982 M | 739 M | 819 M | 841 M | 856 M |
Depreciation & Amortization |
644 M | 577 M | 537 M | 577 M | 625 M | 577 M | 552 M | 533 M | 499 M | 458 M | 246 M | 230 M | 230 M | 231 M |
Accounts Payables |
876 M | 828 M | 852 M | 621 M | 639 M | 632 M | 635 M | 663 M | 508 M | 497 M | 282 M | 304 M | 237 M | 258 M |
Accounts Receivables |
1.94 B | 1.91 B | 1.79 B | 2.26 B | 2.48 B | 1.54 B | 1.47 B | 1.48 B | 1.33 B | 1.22 B | 816 M | 785 M | 718 M | 700 M |
Total Inventories |
493 M | 475 M | 471 M | 401 M | 423 M | 245 M | 237 M | 228 M | 205 M | 191 M | 140 M | 136 M | 121 M | 111 M |
All numbers in USD currency
Quarterly Cash Flow Laboratory Corporation of America Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 18.5 M | - | - | - | -29.8 M | - | - | - | 121 M | - | 1.3 B | - | 356 M | - | 2.41 B | - | 1.16 B | - | 1.36 B | 574 M | 204 M | - | 875 M | 419 M | 166 M | - | 819 M | 567 M | 180 M | - | 933 M | 536 M | 226 M | - | 727 M | 477 M | 128 M | - | 598 M | 310 M | -86.9 M | - | 525 M | 350 M | 739 M | - | 570 M | 336 M | 198 M | - | 587 M | 383 M | 197 M | - | 577 M | 400 M | 215 M |
Depreciation & Amortization |
69.5 M | 68.3 M | 167 M | - | 63.7 M | 62.2 M | 154 M | - | 55.7 M | 51.5 M | 142 M | - | 49 M | 49.8 M | 162 M | - | 557 M | 92.4 M | 184 M | - | 441 M | 288 M | 145 M | - | 421 M | 277 M | 136 M | - | 414 M | 281 M | 143 M | - | 388 M | 255 M | 128 M | - | 369 M | 248 M | 122 M | - | 340 M | 220 M | 103 M | - | 182 M | 124 M | 246 M | - | 170 M | 112 M | 55.5 M | - | 170 M | 113 M | 56.7 M | - | 174 M | 116 M | 58.1 M |
Accounts Payables |
668 M | 793 M | 718 M | 876 M | 661 M | 761 M | 696 M | 828 M | 691 M | 713 M | 881 M | 852 M | 766 M | - | 624 M | 621 M | 669 M | 600 M | 621 M | 639 M | 639 M | 639 M | 639 M | 632 M | 632 M | 632 M | 632 M | 635 M | 635 M | 635 M | 635 M | 574 M | 574 M | 574 M | 576 M | 508 M | 508 M | 508 M | 508 M | 497 M | 497 M | 497 M | 497 M | 282 M | 282 M | 282 M | 282 M | 304 M | 304 M | 304 M | 304 M | 237 M | 237 M | 237 M | 237 M | 258 M | 258 M | 258 M | 258 M |
Accounts Receivables |
2.11 B | 2.12 B | 2.12 B | 1.94 B | 2.06 B | 2.09 B | 2.08 B | 1.91 B | 1.96 B | 1.9 B | 2.34 B | 1.79 B | 2.16 B | - | 2.24 B | 2.26 B | 2.34 B | 2.21 B | 2.32 B | 2.48 B | 2.48 B | 2.48 B | 2.48 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 1.53 B | 1.53 B | 1.53 B | 1.56 B | 1.33 B | 1.33 B | 1.33 B | 1.33 B | 1.22 B | 1.22 B | 1.22 B | 1.22 B | 816 M | 816 M | 816 M | 816 M | 785 M | 785 M | 785 M | 785 M | 718 M | 718 M | 718 M | 718 M | 700 M | 700 M | 700 M | 700 M |
Total Inventories |
522 M | 508 M | 488 M | 493 M | 483 M | 442 M | 475 M | 475 M | 461 M | 488 M | 481 M | 471 M | 468 M | - | 441 M | 401 M | 411 M | 421 M | 428 M | 423 M | 423 M | 423 M | 423 M | 245 M | 245 M | 245 M | 245 M | 237 M | 237 M | 237 M | 237 M | 227 M | 227 M | 227 M | 228 M | 205 M | 205 M | 205 M | 205 M | 191 M | 191 M | 191 M | 191 M | 140 M | 140 M | 140 M | 140 M | 136 M | 136 M | 136 M | 136 M | 121 M | 121 M | 121 M | 121 M | 111 M | 111 M | 111 M | 111 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Laboratory Corporation of America Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
$ 19.14 | 0.63 % | $ 99.4 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 19.97 | -4.84 % | $ 215 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
BioNano Genomics
BNGO
|
$ 1.59 | 3.59 % | $ 2.02 M | ||
|
Co-Diagnostics
CODX
|
$ 5.64 | 11.51 % | $ 166 M | ||
|
Castle Biosciences
CSTL
|
$ 38.43 | -1.21 % | $ 1.07 B | ||
|
Danaher Corporation
DHR
|
$ 230.25 | 0.53 % | $ 168 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
$ 10.5 | -7.73 % | $ 298 M | ||
|
DexCom
DXCM
|
$ 66.65 | 0.42 % | $ 25.7 B | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Exact Sciences Corporation
EXAS
|
$ 101.69 | 0.13 % | $ 18.8 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
$ 25.65 | -2.37 % | $ 776 M | ||
|
CareDx, Inc
CDNA
|
$ 19.11 | 1.43 % | $ 1.03 B | ||
|
Celcuity
CELC
|
$ 100.55 | 0.81 % | $ 3.97 B | ||
|
Anixa Biosciences
ANIX
|
$ 3.14 | 0.64 % | $ 100 K | ||
|
Guardant Health
GH
|
$ 101.73 | -0.4 % | $ 12.5 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
IQVIA Holdings
IQV
|
$ 225.49 | 0.08 % | $ 40.9 B | ||
|
Illumina
ILMN
|
$ 134.02 | 2.18 % | $ 21.3 B | ||
|
Charles River Laboratories International
CRL
|
$ 201.62 | 1.09 % | $ 10.4 B | ||
|
OPKO Health
OPK
|
$ 1.3 | 2.78 % | $ 902 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 173.33 | -0.05 % | $ 19.2 B | ||
|
Biodesix
BDSX
|
$ 6.37 | -6.32 % | $ 826 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 27.15 | 0.22 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
ICON Public Limited Company
ICLR
|
$ 187.85 | 3.09 % | $ 15.5 B | ||
|
IDEXX Laboratories
IDXX
|
$ 671.36 | -0.76 % | $ 55.4 B | ||
|
Lantheus Holdings
LNTH
|
$ 67.25 | 1.05 % | $ 4.65 B | ||
|
Agilent Technologies
A
|
$ 137.32 | 0.87 % | $ 41.7 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 409.97 | 1.13 % | $ 29.9 B | ||
|
Organovo Holdings
ONVO
|
- | -2.3 % | $ 19.4 M | ||
|
Personalis
PSNL
|
$ 7.85 | -1.44 % | $ 465 M | ||
|
Biomerica
BMRA
|
$ 2.51 | -0.39 % | $ 5.77 M | ||
|
Bioventus
BVS
|
$ 7.23 | -2.82 % | $ 453 M | ||
|
Myriad Genetics
MYGN
|
$ 6.18 | 0.41 % | $ 560 M | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M |